India Pharma Outlook Team | Friday, 20 November 2026
Atopic dermatitis treatment development has encountered a setback.
Celldex Therapeutics discontinued its experimental drug barzolvolimab following unsuccessful Phase 2 trial results.
The decision came after the drug failed to meet its primary and key secondary efficacy endpoints in patients with moderate-to-severe atopic dermatitis.
Although barzolvolimab successfully depleted mast cells and demonstrated a favourable safety profile, it did not deliver sufficient improvements in itching or disease severity compared with placebo.
The findings raise questions about the role of mast cells as a primary therapeutic target in atopic dermatitis.
Also Read: Partnerships and Patient-Centric Innovation: Shaping India's Next Pharma Growth Chapter
The Phase 2 trial evaluated two barzolvolimab doses-150 mg and 300 mg-against placebo. Its primary endpoint measured changes in itching using the Peak Pruritus Numerical Rating Scale at Week 16.
Neither dose achieved statistical significance. The placebo group recorded a 19.5 percent improvement, compared with 29.2 percent for the 300 mg group and 16.2 percent for the 150 mg group.
Key secondary measures, including eczema severity and clear or almost-clear skin assessments, also failed to meaningfully differentiate from placebo.
The results suggest that although mast cells contribute to atopic dermatitis, they may not be its primary disease driver. This distinction is important for future atopic dermatitis treatment research.
Celldex is discontinuing development in atopic dermatitis but continues barzolvolimab programs in other inflammatory conditions.
The company is advancing Phase 3 studies in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism.
Celldex expects to submit a Biologics License Application for chronic spontaneous urticaria in 2027. The company also plans to announce additional indications for barzolvolimab by the end of 2026.